Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Immunol.

Sec. Cytokines and Soluble Mediators in Immunity

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1657285

This article is part of the Research TopicAdvancing Musculoskeletal Health: Bridging Basic and Clinical Research on Biomechanical Properties of Joints, Ligaments, Tendons, and Associated StructuresView all 10 articles

Mechanistic insights into IL-1β-mediated progression of tendinopathy

Provisionally accepted
Yuchi  ZhangYuchi Zhang1Jiayue  WangJiayue Wang1Fanbo  TangFanbo Tang1Guoqiang  YangGuoqiang Yang1Guiquan  ChenGuiquan Chen2*
  • 1Southwest Medical University, Luzhou, China
  • 2Luzhou Medical College, Luzhou, China

The final, formatted version of the article will be published soon.

Tendinopathy, a chronic degenerative musculoskeletal disorder characterized by pain, edema, and functional impairment, exhibits increased prevalence among elderly populations and athletes. Despite extensive research efforts targeting the attenuation of this degenerative process, clinical outcomes frequently remain suboptimal. Recent evidence underscores the critical need for more precisely targeted modulation of inflammatory pathways to improve therapeutic efficacy. Notably, the proinflammatory cytokine interleukin-1β (IL-1β) has been implicated as a prominent mediator in the pathogenesis of tendinopathy. This review synthesizes current understanding of IL-1β synthesis and its downstream signaling transduction pathways, with the primary objective of elucidating the mechanisms by which IL-1β contributes to tendinopathy progression. Through this approach, we seek to reveal novel therapeutic targets and inform improved management strategies. Although IL-1β represents a promising therapeutic candidate for tendinopathy, as evidenced by numerous investigations, current understanding of its pathogenic role is limited by several factors, including the heterogeneity of experimental models, a lack of translational studies, and insufficient evidence linking IL-1β signaling to specific clinical manifestations. Consequently, further research is essential to delineate the precise mechanisms of IL-1β involvement in tendinopathy.

Keywords: IL-1β, Tendinopathy, Pathogenesis, therapeutic targets, proinflammatory cytokines

Received: 01 Jul 2025; Accepted: 15 Oct 2025.

Copyright: © 2025 Zhang, Wang, Tang, Yang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Guiquan Chen, lhynn1113@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.